Chongqing Zhifei Bio Products (300122) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has a cash flow conversion efficiency ratio of 0.048x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.42 Billion ≈ $207.88 Million USD) by net assets (CN¥29.61 Billion ≈ $4.33 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Chongqing Zhifei Bio Products worth for the company's overall valuation and market capitalisation.
Chongqing Zhifei Bio Products - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Chongqing Zhifei Bio Products's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Chongqing Zhifei Bio Products Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chongqing Zhifei Bio Products ranked by their cash flow conversion efficiency. Explore 300122 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clear Secure Inc
NYSE:YOU
|
1.610x |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
-0.020x |
|
Almonty Industries Inc. Common Shares
NASDAQ:ALM
|
0.040x |
|
Suzhou HYC Technology Co Ltd
SHG:688001
|
0.058x |
|
Ecovacs Robotics Co Ltd
SHG:603486
|
0.054x |
|
Nanjing Securities Co Ltd
SHG:601990
|
-0.262x |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
0.000x |
|
ENSTAR GROUP LTD DL-01
F:48R
|
N/A |
Annual Cash Flow Conversion Efficiency for Chongqing Zhifei Bio Products (2007–2025)
The table below shows the annual cash flow conversion efficiency of Chongqing Zhifei Bio Products from 2007 to 2025. View Chongqing Zhifei Bio Products stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥16.11 Billion ≈ $2.36 Billion |
CN¥5.17 Billion ≈ $756.14 Million |
0.321x | +324.09% |
| 2024-12-31 | CN¥30.83 Billion ≈ $4.51 Billion |
CN¥-4.41 Billion ≈ $-645.91 Million |
-0.143x | -150.14% |
| 2023-12-31 | CN¥31.51 Billion ≈ $4.61 Billion |
CN¥9.00 Billion ≈ $1.32 Billion |
0.286x | +247.93% |
| 2022-12-31 | CN¥24.24 Billion ≈ $3.55 Billion |
CN¥1.99 Billion ≈ $291.06 Million |
0.082x | -82.97% |
| 2021-12-31 | CN¥17.66 Billion ≈ $2.58 Billion |
CN¥8.51 Billion ≈ $1.24 Billion |
0.482x | +13.66% |
| 2020-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
CN¥3.50 Billion ≈ $511.68 Million |
0.424x | +78.23% |
| 2019-12-31 | CN¥5.75 Billion ≈ $841.02 Million |
CN¥1.37 Billion ≈ $200.03 Million |
0.238x | +69.81% |
| 2018-12-31 | CN¥4.18 Billion ≈ $611.80 Million |
CN¥585.59 Million ≈ $85.69 Million |
0.140x | +102.07% |
| 2017-12-31 | CN¥2.94 Billion ≈ $429.85 Million |
CN¥203.61 Million ≈ $29.79 Million |
0.069x | +94.27% |
| 2016-12-31 | CN¥2.52 Billion ≈ $368.94 Million |
CN¥89.95 Million ≈ $13.16 Million |
0.036x | -60.57% |
| 2015-12-31 | CN¥2.47 Billion ≈ $361.33 Million |
CN¥223.45 Million ≈ $32.70 Million |
0.090x | +37.81% |
| 2014-12-31 | CN¥2.46 Billion ≈ $359.64 Million |
CN¥161.39 Million ≈ $23.62 Million |
0.066x | -29.19% |
| 2013-12-31 | CN¥2.39 Billion ≈ $349.62 Million |
CN¥221.58 Million ≈ $32.42 Million |
0.093x | +94.94% |
| 2012-12-31 | CN¥2.37 Billion ≈ $347.24 Million |
CN¥112.89 Million ≈ $16.52 Million |
0.048x | -51.45% |
| 2011-12-31 | CN¥2.26 Billion ≈ $330.43 Million |
CN¥221.25 Million ≈ $32.38 Million |
0.098x | +287.24% |
| 2010-12-31 | CN¥2.14 Billion ≈ $313.40 Million |
CN¥54.19 Million ≈ $7.93 Million |
0.025x | -94.57% |
| 2009-12-31 | CN¥451.69 Million ≈ $66.10 Million |
CN¥210.61 Million ≈ $30.82 Million |
0.466x | -12.05% |
| 2008-12-31 | CN¥267.06 Million ≈ $39.08 Million |
CN¥141.58 Million ≈ $20.72 Million |
0.530x | -10.72% |
| 2007-12-31 | CN¥188.03 Million ≈ $27.52 Million |
CN¥111.66 Million ≈ $16.34 Million |
0.594x | -- |
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide… Read more